revenu ep modest beat ep guidanc increas
ep estim consensu
ep guidanc increas prior rais ep
estim ep guidanc lower
price base reduc target pe ep prior given
linger uncertainti legal price biosimilar surround humira apt keep
lid pe multipl albeit clariti eu biosimilar forthcom
sale estim
consensu drug beat estim includ mavyret humira
sevofluoran imbruvica lupron kaletra creon duodopa
combin forecast androgel synthroid combin light
full year sale guidanc tweak approach approach
reflect neg fx impact last publish revenu
estim
gpm line estim
estim sg forecast net interest
expens forecast pre-tax margin
estim tax rate estim share count
estim clip ep updat guidanc
 item gpm vs prior approxim approach
sale vs prior sale oper margin vs prior
imbruvica ph ii data pancreat cancer resolv imbruvica gazyva file
cll/sll imbruvica rituxan /eu approv wm pdufa dec venclexta ph
data cll w/gazyva ph ii data r/r fl contralto dlbcl
caval initi ph mm mainten late eu approv r/r cll
w/rituxan upadacitinib file ra initi ph atop dermat uc
risankizumab initi ph late orilissa elagolix full ph
data uterin fibroid posit top-lin veliparib ph data vela non-sq nsclc
pleas see page report import disclosur
provid long-term guidanc expect humira appear
solid foot forese futur competit posit
hepat segment oncolog compani pipelin promis
agent opportun upward revis sever front stock
attract valu versu group overal attribut argu purchas
upadacitinib /eu file ra
venclexta ph ii/iii data numer trial
humira sale
biosimilar competit
humira biosimilar gain traction
quickli eu and/or launch
especi oncolog
global biopharmaceut compani product use treat rheumatoid
chronic kidney diseas among other humira ra crohn domin
product repres total sale profit also pipelin
compound indic phase ii phase develop
cowen compani
chg total good profit margin profit gross gross profit profit gross gross profit oper foreign exchang gain expens incom expens incom share cowen
cowen compani
reportedour estimatedifferenceproduct exceed cowen
cowen compani
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ heavi depend humira sale ep success pipelin
product notabl hepat portfolio success independ compani
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
